25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Cidara Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Cidara together

I guess you are interested in Cidara Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cidara Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cidara Therapeutics Inc

I send you an email if I find something interesting about Cidara Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cidara (30 sec.)










1.2. What can you expect buying and holding a share of Cidara? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$10.56
Expected worth in 1 year
$20.39
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$9.83
Return On Investment
41.1%

For what price can you sell your share?

Current Price per Share
$23.94
Expected price per share
$13.92 - $42.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cidara (5 min.)




Live pricePrice per Share (EOD)
$23.94
Intrinsic Value Per Share
$-154.56 - $-89.60
Total Value Per Share
$-143.99 - $-79.04

2.2. Growth of Cidara (5 min.)




Is Cidara growing?

Current yearPrevious yearGrowGrow %
How rich?$115.6m$11.8m$43.2m78.5%

How much money is Cidara making?

Current yearPrevious yearGrowGrow %
Making money-$30.2m-$7.7m-$22.4m-74.4%
Net Profit Margin-7,440.0%-86.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Cidara (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#329 / 925

Most Revenue
#320 / 925

Most Profit
#737 / 925

Most Efficient
#839 / 925
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cidara?

Welcome investor! Cidara's management wants to use your money to grow the business. In return you get a share of Cidara.

First you should know what it really means to hold a share of Cidara. And how you can make/lose money.

Speculation

The Price per Share of Cidara is $23.94. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cidara.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cidara, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.56. Based on the TTM, the Book Value Change Per Share is $2.46 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cidara.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.42-5.9%-2.76-11.5%-0.69-2.9%-1.39-5.8%-1.25-5.2%
Usd Book Value Change Per Share-1.40-5.8%2.4610.3%-0.02-0.1%0.301.3%0.271.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.40-5.8%2.4610.3%-0.02-0.1%0.301.3%0.271.1%
Usd Price Per Share10.75-6.10-1.02-2.68-4.87-
Price to Earnings Ratio-1.89--0.72-0.16--0.25--0.93-
Price-to-Total Gains Ratio-7.69--2.10--0.68--1.17--3.03-
Price to Book Ratio1.02-0.10--0.06-0.20-0.60-
Price-to-Total Gains Ratio-7.69--2.10--0.68--1.17--3.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share23.94
Number of shares41
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.460.30
Usd Total Gains Per Share2.460.30
Gains per Quarter (41 shares)100.7612.49
Gains per Year (41 shares)403.0349.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1040339305040
20806796010090
30120911990150140
40161216020200190
50201520050250240
60241824080300290
70282128110350340
80322432140400390
90362736170450440
100403040200499490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%4.036.00.010.0%4.039.01.09.1%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%12.028.00.030.0%12.029.03.027.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%12.028.00.030.0%12.029.03.027.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cidara Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.3982.458-157%-0.024-98%0.305-559%0.267-623%
Book Value Per Share--10.5645.038+110%1.082+876%2.217+377%4.117+157%
Current Ratio--3.5362.352+50%1.834+93%1.922+84%6.896-49%
Debt To Asset Ratio--0.2880.748-62%0.845-66%0.770-63%0.509-43%
Debt To Equity Ratio--0.4040.182+122%3.088-87%3.537-89%1.894-79%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--198345900.00088255415.200+125%2816975.550+6941%33180545.068+498%90893505.878+118%
Eps---1.419-2.761+95%-0.693-51%-1.387-2%-1.253-12%
Ev To Ebitda Ratio---2.861inf+inf%0.115-2579%inf+inf%inf+inf%
Ev To Sales Ratio--infinfnan%0.060+inf%infnan%infnan%
Free Cash Flow Per Share---3.362-3.658+9%-0.709-79%-1.342-60%-1.108-67%
Free Cash Flow To Equity Per Share---3.3791.798-288%0.098-3559%0.284-1288%0.252-1441%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---89.602--------
Intrinsic Value_10Y_min---154.556--------
Intrinsic Value_1Y_max---5.096--------
Intrinsic Value_1Y_min---8.085--------
Intrinsic Value_3Y_max---18.270--------
Intrinsic Value_3Y_min---30.847--------
Intrinsic Value_5Y_max---35.013--------
Intrinsic Value_5Y_min---60.620--------
Market Cap262028088.000+55%117660900.00066776665.200+76%11214725.550+949%29279395.068+302%53285830.584+121%
Net Profit Margin----74.4000%-0.8650%-17.4790%-8.7350%
Operating Margin----9.5110%-0.9150%-4.4940%-2.2430%
Operating Ratio---10.358-100%1.902-100%5.786-100%2.929-100%
Pb Ratio2.266+55%1.0180.098+942%-0.062+106%0.201+406%0.598+70%
Pe Ratio-4.217-123%-1.893-0.722-62%0.160-1285%-0.253-87%-0.934-51%
Price Per Share23.940+55%10.7506.101+76%1.025+949%2.675+302%4.868+121%
Price To Free Cash Flow Ratio-1.780-123%-0.799-0.415-48%-0.185-77%-0.430-46%-1.218+52%
Price To Total Gains Ratio-17.119-123%-7.687-2.099-73%-0.676-91%-1.167-85%-3.035-61%
Quick Ratio--2.9111.978+47%1.646+77%1.682+73%8.460-66%
Return On Assets---0.096-0.223+133%-0.139+45%-0.197+106%-0.171+79%
Return On Equity---0.134-0.204+52%-0.427+217%-0.919+584%-0.549+309%
Total Gains Per Share---1.3982.458-157%-0.024-98%0.305-559%0.267-623%
Usd Book Value--115630000.00055144000.000+110%11846250.000+876%24266350.000+377%45064575.000+157%
Usd Book Value Change Per Share---1.3982.458-157%-0.024-98%0.305-559%0.267-623%
Usd Book Value Per Share--10.5645.038+110%1.082+876%2.217+377%4.117+157%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--198345900.00088255415.200+125%2816975.550+6941%33180545.068+498%90893505.878+118%
Usd Eps---1.419-2.761+95%-0.693-51%-1.387-2%-1.253-12%
Usd Free Cash Flow---36801000.000-40037000.000+9%-7762000.000-79%-14692150.000-60%-12123225.000-67%
Usd Free Cash Flow Per Share---3.362-3.658+9%-0.709-79%-1.342-60%-1.108-67%
Usd Free Cash Flow To Equity Per Share---3.3791.798-288%0.098-3559%0.284-1288%0.252-1441%
Usd Market Cap262028088.000+55%117660900.00066776665.200+76%11214725.550+949%29279395.068+302%53285830.584+121%
Usd Price Per Share23.940+55%10.7506.101+76%1.025+949%2.675+302%4.868+121%
Usd Profit---15535000.000-30220500.000+95%-7723250.000-50%-14995250.000-3%-13168125.000-15%
Usd Revenue---6587000.000-100%14135250.000-100%10020600.000-100%5487800.000-100%
Usd Total Gains Per Share---1.3982.458-157%-0.024-98%0.305-559%0.267-623%
 EOD+5 -3MRQTTM+23 -12YOY+18 -175Y+18 -1710Y+15 -20

3.3 Fundamental Score

Let's check the fundamental score of Cidara Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.217
Price to Book Ratio (EOD)Between0-12.266
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.911
Current Ratio (MRQ)Greater than13.536
Debt to Asset Ratio (MRQ)Less than10.288
Debt to Equity Ratio (MRQ)Less than10.404
Return on Equity (MRQ)Greater than0.15-0.134
Return on Assets (MRQ)Greater than0.05-0.096
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cidara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.664
Ma 20Greater thanMa 5020.736
Ma 50Greater thanMa 10022.113
Ma 100Greater thanMa 20017.597
OpenGreater thanClose23.220
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Fundamental data was last updated by Penke on 2025-02-06 13:58:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cidara earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cidara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-7,440.0%+7,440.0%
TTM-7,440.0%YOY-86.5%-7,353.5%
TTM-7,440.0%5Y-1,747.9%-5,692.1%
5Y-1,747.9%10Y-873.5%-874.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--100.3%+100.3%
TTM-7,440.0%-211.5%-7,228.5%
YOY-86.5%-213.8%+127.3%
5Y-1,747.9%-346.2%-1,401.7%
10Y-873.5%-489.2%-384.3%
4.3.1.2. Return on Assets

Shows how efficient Cidara is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Cidara generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cidara Therapeutics Inc:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-22.3%+12.7%
TTM-22.3%YOY-13.9%-8.4%
TTM-22.3%5Y-19.7%-2.6%
5Y-19.7%10Y-17.1%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-12.0%+2.4%
TTM-22.3%-12.1%-10.2%
YOY-13.9%-11.4%-2.5%
5Y-19.7%-12.8%-6.9%
10Y-17.1%-14.6%-2.5%
4.3.1.3. Return on Equity

Shows how efficient Cidara is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • -13.4% Return on Equity means Cidara generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cidara Therapeutics Inc:

  • The MRQ is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.4%TTM-20.4%+7.0%
TTM-20.4%YOY-42.7%+22.2%
TTM-20.4%5Y-91.9%+71.4%
5Y-91.9%10Y-54.9%-36.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.4%-15.4%+2.0%
TTM-20.4%-16.2%-4.2%
YOY-42.7%-14.7%-28.0%
5Y-91.9%-18.6%-73.3%
10Y-54.9%-19.5%-35.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cidara Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cidara is operating .

  • Measures how much profit Cidara makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cidara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-951.1%+951.1%
TTM-951.1%YOY-91.5%-859.6%
TTM-951.1%5Y-449.4%-501.7%
5Y-449.4%10Y-224.3%-225.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM-951.1%-313.4%-637.7%
YOY-91.5%-215.2%+123.7%
5Y-449.4%-371.8%-77.6%
10Y-224.3%-492.1%+267.8%
4.3.2.2. Operating Ratio

Measures how efficient Cidara is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.358-10.358
TTM10.358YOY1.902+8.456
TTM10.3585Y5.786+4.572
5Y5.78610Y2.929+2.857
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.139-2.139
TTM10.3583.198+7.160
YOY1.9023.358-1.456
5Y5.7864.842+0.944
10Y2.9296.500-3.571
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cidara Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cidara is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.54 means the company has $3.54 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 3.536. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.352. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.536TTM2.352+1.184
TTM2.352YOY1.834+0.518
TTM2.3525Y1.922+0.430
5Y1.92210Y6.896-4.974
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5363.610-0.074
TTM2.3523.871-1.519
YOY1.8344.609-2.775
5Y1.9225.977-4.055
10Y6.8966.216+0.680
4.4.3.2. Quick Ratio

Measures if Cidara is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • A Quick Ratio of 2.91 means the company can pay off $2.91 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 2.911. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.978. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.911TTM1.978+0.933
TTM1.978YOY1.646+0.333
TTM1.9785Y1.682+0.296
5Y1.68210Y8.460-6.778
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9113.085-0.174
TTM1.9783.360-1.382
YOY1.6464.400-2.754
5Y1.6825.972-4.290
10Y8.4606.483+1.977
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cidara Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cidara assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cidara to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Cidara assets are financed with 28.8% credit (debt) and the remaining percentage (100% - 28.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.288. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.748. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.288TTM0.748-0.460
TTM0.748YOY0.845-0.097
TTM0.7485Y0.770-0.022
5Y0.77010Y0.509+0.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2880.341-0.053
TTM0.7480.343+0.405
YOY0.8450.315+0.530
5Y0.7700.363+0.407
10Y0.5090.384+0.125
4.5.4.2. Debt to Equity Ratio

Measures if Cidara is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cidara to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.4% means that company has $0.40 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.404. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.182. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.404TTM0.182+0.222
TTM0.182YOY3.088-2.906
TTM0.1825Y3.537-3.355
5Y3.53710Y1.894+1.643
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4040.386+0.018
TTM0.1820.429-0.247
YOY3.0880.391+2.697
5Y3.5370.450+3.087
10Y1.8940.495+1.399
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cidara generates.

  • Above 15 is considered overpriced but always compare Cidara to the Biotechnology industry mean.
  • A PE ratio of -1.89 means the investor is paying $-1.89 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cidara Therapeutics Inc:

  • The EOD is -4.217. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.893. Based on the earnings, the company is expensive. -2
  • The TTM is -0.722. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.217MRQ-1.893-2.323
MRQ-1.893TTM-0.722-1.171
TTM-0.722YOY0.160-0.882
TTM-0.7225Y-0.253-0.469
5Y-0.25310Y-0.934+0.681
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.217-2.247-1.970
MRQ-1.893-2.706+0.813
TTM-0.722-3.253+2.531
YOY0.160-3.392+3.552
5Y-0.253-6.132+5.879
10Y-0.934-6.735+5.801
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cidara Therapeutics Inc:

  • The EOD is -1.780. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.799. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.415. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.780MRQ-0.799-0.981
MRQ-0.799TTM-0.415-0.384
TTM-0.415YOY-0.185-0.230
TTM-0.4155Y-0.430+0.015
5Y-0.43010Y-1.218+0.787
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.780-3.026+1.246
MRQ-0.799-3.582+2.783
TTM-0.415-3.816+3.401
YOY-0.185-4.463+4.278
5Y-0.430-8.265+7.835
10Y-1.218-9.266+8.048
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cidara is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.02 means the investor is paying $1.02 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cidara Therapeutics Inc:

  • The EOD is 2.266. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.018. Based on the equity, the company is underpriced. +1
  • The TTM is 0.098. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.266MRQ1.018+1.249
MRQ1.018TTM0.098+0.920
TTM0.098YOY-0.062+0.159
TTM0.0985Y0.201-0.103
5Y0.20110Y0.598-0.397
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2661.948+0.318
MRQ1.0182.223-1.205
TTM0.0982.427-2.329
YOY-0.0622.469-2.531
5Y0.2013.767-3.566
10Y0.5984.507-3.909
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cidara Therapeutics Inc.

4.8.1. Institutions holding Cidara Therapeutics Inc

Institutions are holding 51.858% of the shares of Cidara Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30RA Capital Management, LLC6.42360.08717030807030800
2024-09-30Bain Capital Life Sciences Investors, LLC6.42360.78637030807030800
2024-09-30Bvf Inc6.42350.2211703065360010104.9424
2024-09-30Monashee Investment Management LLC3.37220.429636909900
2024-09-30Checkpoint Capital LP1.66670.97291824263700925.4503
2024-09-30Vanguard Group Inc1.6494018053500
2024-09-30Renaissance Technologies Corp0.89370.00169781723002.4079
2024-09-30Alethea Capital Management, LLC0.73010.62047990800
2024-09-305AM Venture Management, LLC0.51830.1265672500
2024-09-30Geode Capital Management, LLC0.48330.000152898977122.6563
2024-09-30BlackRock Inc0.4470489204080.841
2024-09-30Adage Capital Partners Gp LLC0.39060.000842755427550
2024-09-30Northern Trust Corp0.29040.000131787317870
2024-09-30Schonfeld Strategic Advisors LLC0.17820.0014195001000.5155
2024-09-30Millennium Management LLC0.12720.000113919139190
2024-09-30State Street Corp0.12401357600
2024-09-30UBS Group AG0.0537058774410300.6135
2024-09-30Tower Research Capital LLC0.01020.0003111536949.4638
2024-09-30Acadian Asset Management LLC0.0078085500
2024-12-31Manchester Capital Management LLC0.00430.001547000
Total 30.21783.24933307407+1908998+57.7%

4.9.2. Funds holding Cidara Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Vanguard Total Stock Mkt Idx Inv1.11050.000212155000
2024-12-31Vanguard Institutional Extnd Mkt Idx Tr0.81640.0021893563696970.569
2024-12-31Fidelity Extended Market Index0.24610.001826932-217-0.7993
2024-12-31A4Investments SICAV SIF ACCI IlanaA2EURH0.22849.586925000-10500-29.5775
2024-09-30Vifag 2002 SICAV0.22280.37362438900
2024-05-31Sun Life CC&L Group Income & Growth Seg0.16020.00617529175290
2024-12-31Extended Equity Market Fund K0.09840.00210767-148-1.3559
2025-01-29iShares Micro-Cap ETF0.09180.01851005300
2024-12-31Fidelity Total Market Index0.08490.0002929700
2024-12-31Northern Small Cap Core I0.06940.044760000
2024-12-31Fidelity Series Total Market Index0.05740.00026287-156-2.4212
2024-12-31NT Ext Equity Mkt Idx Fd - L0.05050.00185524217064.6989
2024-12-31Northern Trust Extended Eq Market Idx0.05050.00185524217064.6989
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.04020.0018439700
2024-12-31Fidelity Nasdaq Composite Index0.03620.0006396764419.3801
2024-12-31Spartan Extended Market Index Pool E0.03580.001739132175.8712
2024-09-30NT Quality Small Cap Core0.03510.0203383838380
2024-12-31NT Quality SCC US Fund - L0.03510.0487383800
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03180.00183485-58-1.637
2024-12-31Vanguard Balanced Index Inv0.02710.0001296600
Total 3.528610.1141386212+52458+13.6%

5.3. Insider Transactions

Insiders are holding 4.73% of the shares of Cidara Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-11Taylor SandisonSELL92411.64
2024-06-07Jeffrey SteinBUY800013.21
2024-03-11Leslie TariSELL105113.4
2024-03-11Preetam ShahSELL94613.4
2024-03-11Shane WardSELL102313.4
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets162,331
Total Liabilities46,701
Total Stockholder Equity115,630
 As reported
Total Liabilities 46,701
Total Stockholder Equity+ 115,630
Total Assets = 162,331

Assets

Total Assets162,331
Total Current Assets156,771
Long-term Assets5,560
Total Current Assets
Cash And Cash Equivalents 127,386
Net Receivables 1,699
Other Current Assets 27,686
Total Current Assets  (as reported)156,771
Total Current Assets  (calculated)156,771
+/-0
Long-term Assets
Property Plant Equipment 4,318
Long-term Assets Other 1,242
Long-term Assets  (as reported)5,560
Long-term Assets  (calculated)5,560
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities44,339
Long-term Liabilities2,362
Total Stockholder Equity115,630
Total Current Liabilities
Short-term Debt 1,581
Accounts payable 2,967
Other Current Liabilities 13,502
Total Current Liabilities  (as reported)44,339
Total Current Liabilities  (calculated)18,050
+/- 26,289
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,362
Long-term Liabilities  (as reported)2,362
Long-term Liabilities  (calculated)2,362
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -558,951
Other Stockholders Equity 674,580
Total Stockholder Equity (as reported)115,630
Total Stockholder Equity (calculated)115,630
+/-0
Other
Capital Stock1
Cash and Short Term Investments 127,386
Common Stock Shares Outstanding 6,530
Liabilities and Stockholders Equity 162,331
Net Debt -123,443
Net Invested Capital 115,630
Net Working Capital 112,432
Property Plant and Equipment Gross 4,318
Short Long Term Debt Total 3,943



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
201
0
0
0
24,350
60,783
123,953
116,988
109,974
99,223
90,024
82,232
106,962
92,763
81,158
67,436
79,035
70,247
107,008
92,809
79,112
64,313
51,752
81,696
68,976
84,097
73,403
63,669
60,424
54,210
63,744
51,206
75,325
55,295
39,524
66,858
47,593
81,736
67,986
63,468
67,030
52,716
173,357
162,331
162,331173,35752,71667,03063,46867,98681,73647,59366,85839,52455,29575,32551,20663,74454,21060,42463,66973,40384,09768,97681,69651,75264,31379,11292,809107,00870,24779,03567,43681,15892,763106,96282,23290,02499,223109,974116,988123,95360,78324,350000201
   > Total Current Assets 
0
0
0
0
23,013
58,402
123,050
115,365
108,218
97,517
88,231
80,579
105,398
91,281
79,803
66,203
77,670
68,990
105,994
91,961
77,129
60,276
47,746
77,488
65,814
80,621
70,039
60,187
57,191
51,301
61,076
47,276
71,698
52,007
36,546
63,899
45,094
79,488
62,240
57,704
60,855
46,834
168,588
156,771
156,771168,58846,83460,85557,70462,24079,48845,09463,89936,54652,00771,69847,27661,07651,30157,19160,18770,03980,62165,81477,48847,74660,27677,12991,961105,99468,99077,67066,20379,80391,281105,39880,57988,23197,517108,218115,365123,05058,40223,0130000
       Cash And Cash Equivalents 
185
0
0
0
22,796
58,124
122,301
64,471
107,514
51,704
29,271
24,622
104,619
82,198
78,012
54,276
75,314
52,218
88,954
83,780
74,562
57,407
44,573
73,824
60,268
64,314
54,826
45,520
35,912
42,863
48,284
36,601
62,273
36,488
24,637
53,078
32,731
47,976
50,430
48,670
35,778
29,018
164,369
127,386
127,386164,36929,01835,77848,67050,43047,97632,73153,07824,63736,48862,27336,60148,28442,86335,91245,52054,82664,31460,26873,82444,57357,40774,56283,78088,95452,21875,31454,27678,01282,198104,61924,62229,27151,704107,51464,471122,30158,12422,796000185
       Short-term Investments 
0
0
0
0
44,952
0
0
49,947
44,952
44,954
57,818
54,687
19,252
7,888
0
9,876
14,501
13,973
14,246
4,494
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000004,49414,24613,97314,5019,87607,88819,25254,68757,81844,95444,95249,9470044,9520000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
190
190
190
215
321
321
288
41
62
1,271
1,271
1,446
1,902
5,546
6,307
5,954
6,519
11,175
11
3,157
3,872
5,356
8,783
4,833
5,042
5,833
25,826
5,483
2,855
16,246
7,281
2,349
1,699
1,6992,3497,28116,2462,8555,48325,8265,8335,0424,8338,7835,3563,8723,1571111,1756,5195,9546,3075,5461,9021,4461,2711,271624128832132121519019019000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-321
0
0
0
0
0
0
0
-5,546
0
0
0
0
0
0
0
-2,593
0
0
0
0
0
1,954
2,467
6,097
7,269
0
0
007,2696,0972,4671,95400000-2,5930000000-5,5460000000-3210000000000000000
   > Long-term Assets 
0
0
0
0
1,337
2,381
903
1,623
1,756
1,706
1,793
1,653
1,564
1,482
1,355
1,233
1,365
1,257
1,014
848
1,983
4,037
4,006
4,208
3,162
3,476
3,364
3,482
3,233
2,909
2,668
3,930
3,627
3,288
2,978
2,959
2,499
2,248
5,746
5,764
6,175
5,882
4,769
5,560
5,5604,7695,8826,1755,7645,7462,2482,4992,9592,9783,2883,6273,9302,6682,9093,2333,4823,3643,4763,1624,2084,0064,0371,9838481,0141,2571,3651,2331,3551,4821,5641,6531,7931,7061,7561,6239032,3811,3370000
       Property Plant Equipment 
0
0
0
0
863
814
831
1,550
1,684
1,634
1,603
1,463
1,374
1,292
1,165
1,043
1,044
936
824
786
712
2,766
2,560
2,306
2,061
1,841
1,729
1,459
1,210
948
707
2,756
2,543
2,269
1,965
1,664
1,427
1,187
4,685
4,711
5,127
4,895
4,665
4,318
4,3184,6654,8955,1274,7114,6851,1871,4271,6641,9652,2692,5432,7567079481,2101,4591,7291,8412,0612,3062,5602,7667127868249361,0441,0431,1651,2921,3741,4631,6031,6341,6841,5508318148630000
       Long-term Assets Other 
0
0
0
0
474
1,567
72
73
72
72
190
190
190
190
190
190
321
321
190
62
1,271
1,271
1,446
1,902
1,101
1,635
1,635
2,023
2,023
1,961
1,961
1,174
1,084
1,019
1,013
1,295
1,072
1,061
1,061
1,053
1,048
987
104
1,242
1,2421049871,0481,0531,0611,0611,0721,2951,0131,0191,0841,1741,9611,9612,0232,0231,6351,6351,1011,9021,4461,2711,27162190321321190190190190190190727273721,5674740000
> Total Liabilities 
1,599
0
0
0
3,247
78,309
3,096
4,363
6,062
4,145
5,215
8,317
18,783
16,774
19,894
16,863
19,291
19,328
24,870
22,877
19,973
20,451
19,970
32,734
31,141
30,345
32,051
34,116
49,709
52,318
47,955
52,364
53,752
50,338
47,485
57,791
50,497
54,899
52,572
55,430
75,240
70,496
42,421
46,701
46,70142,42170,49675,24055,43052,57254,89950,49757,79147,48550,33853,75252,36447,95552,31849,70934,11632,05130,34531,14132,73419,97020,45119,97322,87724,87019,32819,29116,86319,89416,77418,7838,3175,2154,1456,0624,3633,09678,3093,2470001,599
   > Total Current Liabilities 
116
0
0
0
3,213
3,809
3,068
4,275
5,974
4,056
5,125
8,232
8,909
6,886
10,658
8,617
12,085
11,519
14,918
13,562
19,892
18,897
18,608
31,579
30,199
29,629
31,567
33,871
38,564
39,966
33,887
33,490
34,017
32,105
31,455
33,049
29,972
35,663
31,420
35,620
67,418
65,425
39,643
44,339
44,33939,64365,42567,41835,62031,42035,66329,97233,04931,45532,10534,01733,49033,88739,96638,56433,87131,56729,62930,19931,57918,60818,89719,89213,56214,91811,51912,0858,61710,6586,8868,9098,2325,1254,0565,9744,2753,0683,8093,213000116
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
667
1,667
2,667
2,083
5,374
667
9,928
10,668
10,710
10,748
10,783
10,814
10,112
9,039
7,962
6,632
5,292
4,729
3,739
2,671
1,603
1,277
1,317
1,001
942
1,051
0
1,464
3,044
1,581
1,5813,0441,46401,0519421,0011,3171,2771,6032,6713,7394,7295,2926,6327,9629,03910,11210,81410,78310,74810,71010,6689,9286675,3742,0832,6671,6676679,8139,794000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
9,832
1,667
2,667
2,083
9,910
667
9,928
9,938
9,948
9,958
9,965
9,966
9,234
8,129
7,023
5,916
4,808
3,700
2,591
1,481
370
0
0
0
0
0
0
0
0
0
0000000003701,4812,5913,7004,8085,9167,0238,1299,2349,9669,9659,9589,9489,9389,9286679,9102,0832,6671,6679,8329,8139,794000000000000
       Accounts payable 
32
0
0
0
1,177
1,696
854
1,338
3,095
1,266
1,517
2,957
2,909
1,912
4,817
1,777
2,590
2,999
2,611
2,439
2,846
1,713
1,787
2,679
1,887
2,560
2,933
2,024
4,568
3,215
2,587
3,242
1,301
2,861
3,091
4,244
1,447
3,980
1,899
3,661
3,772
5,055
2,288
2,967
2,9672,2885,0553,7723,6611,8993,9801,4474,2443,0912,8611,3013,2422,5873,2154,5682,0242,9332,5601,8872,6791,7871,7132,8462,4392,6112,9992,5901,7774,8171,9122,9092,9571,5171,2663,0951,3388541,6961,17700032
       Other Current Liabilities 
84
0
0
0
2,036
2,113
2,214
2,937
2,879
2,790
3,608
5,275
6,000
4,974
5,174
5,173
6,828
6,437
12,307
4,486
411
681
6,111
7,252
7,726
5,976
7,326
9,717
12,169
14,708
11,547
12,489
15,057
12,313
12,031
12,279
12,594
14,921
13,604
16,229
0
13,964
8,228
13,502
13,5028,22813,964016,22913,60414,92112,59412,27912,03112,31315,05712,48911,54714,70812,1699,7177,3265,9767,7267,2526,1116814114,48612,3076,4376,8285,1735,1744,9746,0005,2753,6082,7902,8792,9372,2142,1132,03600084
   > Long-term Liabilities 
0
0
0
0
34
74,500
28
88
6,062
89
90
85
9,874
9,888
9,236
8,246
7,206
7,809
9,952
9,315
81
1,554
1,362
1,155
942
716
484
245
11,145
12,352
14,068
18,874
19,735
18,233
16,030
24,742
20,525
19,236
21,152
19,810
7,822
5,071
2,778
2,362
2,3622,7785,0717,82219,81021,15219,23620,52524,74216,03018,23319,73518,87414,06812,35211,1452454847169421,1551,3621,554819,3159,9527,8097,2068,2469,2369,8889,8748590896,062882874,500340000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
9,165
8,185
7,206
7,809
9,910
9,253
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000009,2539,9107,8097,2068,1859,1659,8139,794000000000000
       Warrants
0
0
0
0
0
74,469
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000074,46900000
       Other Liabilities 
0
0
0
0
34
31
28
88
88
89
90
85
80
75
71
61
0
0
42
62
81
0
0
0
31,141
0
0
0
11,145
12,352
14,068
17,254
18,413
17,229
15,351
24,398
0
0
17,551
0
0
0
0
0
0000017,5510024,39815,35117,22918,41317,25414,06812,35211,14500031,141000816242006171758085908988882831340000
> Total Stockholder Equity
0
0
0
0
21,103
-17,526
120,857
112,625
103,912
95,078
84,809
73,915
88,179
75,989
61,264
50,573
59,744
50,919
82,138
69,932
59,139
43,862
31,782
48,962
37,835
53,752
41,352
29,553
10,715
1,892
15,789
-1,158
21,573
4,957
-7,961
9,067
-2,904
26,837
15,414
8,038
-8,210
-17,780
130,936
115,630
115,630130,936-17,780-8,2108,03815,41426,837-2,9049,067-7,9614,95721,573-1,15815,7891,89210,71529,55341,35253,75237,83548,96231,78243,86259,13969,93282,13850,91959,74450,57361,26475,98988,17973,91584,80995,078103,912112,625120,857-17,52621,1030000
   Common Stock
0
0
0
0
1
3
4
4
1
1
1
1
2
2
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
5
5
5
7
7
7
7
7
9
9
9
0
1
1
1
11109997777755544443333333222222111144310000
   Retained Earnings Total Equity00000-416,114-403,757-406,96600000-342,281-352,992-334,700-313,066-295,434-277,100-259,800-245,804-248,843-235,300-218,700-206,393-192,800-166,100-149,390-136,000-123,705-107,100-93,662-79,268-67,041-55,286-45,497-35,629-26,455-20,04100000
   Accumulated Other Comprehensive Income 000000000000000000-2,842-2,842000-2,543-1-3-18-8-10-4-1-17-4-2-8-5-123,953-32,548-1790000
   Capital Surplus 
0
0
0
0
0
2,512
147,308
148,255
149,416
150,365
151,853
153,199
181,840
183,051
184,967
186,534
209,140
217,073
274,912
276,323
277,871
279,155
280,622
294,763
297,659
330,876
336,782
342,615
345,411
354,879
358,065
0
0
0
0
0
404,055
430,585
431,519
0
0
0
0
0
00000431,519430,585404,05500000358,065354,879345,411342,615336,782330,876297,659294,763280,622279,155277,871276,323274,912217,073209,140186,534184,967183,051181,840153,199151,853150,365149,416148,255147,3082,51200000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
34,586
2,512
147,308
31,267
149,416
150,365
151,853
153,199
181,840
183,051
184,967
186,534
209,140
217,073
274,912
276,323
277,871
279,155
280,622
294,763
300,501
330,876
336,782
342,615
345,411
354,879
358,065
359,201
398,733
400,398
400,599
402,649
404,055
430,585
431,519
432,315
0
433,976
673,901
674,580
674,580673,901433,9760432,315431,519430,585404,055402,649400,599400,398398,733359,201358,065354,879345,411342,615336,782330,876300,501294,763280,622279,155277,871276,323274,912217,073209,140186,534184,967183,051181,840153,199151,853150,365149,41631,267147,3082,51234,5860000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.